Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc operates in various business sectors.
Osmotica Pharmaceuticals plc (O1P) - Net Assets
Latest net assets as of June 2023: €16.33 Million EUR
Based on the latest financial reports, Osmotica Pharmaceuticals plc (O1P) has net assets worth €16.33 Million EUR as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€85.40 Million) and total liabilities (€69.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €16.33 Million |
| % of Total Assets | 19.12% |
| Annual Growth Rate | -39.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 21.29 |
Osmotica Pharmaceuticals plc - Net Assets Trend (2018–2022)
This chart illustrates how Osmotica Pharmaceuticals plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Osmotica Pharmaceuticals plc (2018–2022)
The table below shows the annual net assets of Osmotica Pharmaceuticals plc from 2018 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €51.09 Million | -33.41% |
| 2021-12-31 | €76.73 Million | -18.24% |
| 2020-12-31 | €93.86 Million | -18.18% |
| 2019-12-31 | €114.71 Million | -70.30% |
| 2018-12-31 | €386.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Osmotica Pharmaceuticals plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46686232800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €620.32 Million | 1214.09% |
| Total Equity | €51.09 Million | 100.00% |
Osmotica Pharmaceuticals plc Competitors by Market Cap
The table below lists competitors of Osmotica Pharmaceuticals plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cann American Corp
PINK:CNNA
|
$38.62 |
|
Triad Pro Innovators Inc
PINK:TPII
|
$38.81 |
|
United Rail Inc
PINK:URAL
|
$39.15 |
|
ABC TRANSPORT PLC
XNSA:ABCTRANS
|
$39.17 |
|
FTN COCOA PROCESSORS PLC
XNSA:FTNCOCOA
|
$38.40 |
|
Gresham House Renewable Energy VCT 1 plc
LSE:GV1O
|
$38.36 |
|
RKRWF
PINK:RKRWF
|
$38.31 |
|
LIPPO SECS -A- (LPS1.SG)
STU:LPS1
|
$38.17 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Osmotica Pharmaceuticals plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 76,733,000 to 51,093,000, a change of -25,640,000 (-33.4%).
- Net loss of 51,692,000 reduced equity.
- New share issuances of 23,634,000 increased equity.
- Other factors increased equity by 2,418,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-51.69 Million | -101.17% |
| Share Issuances | €23.63 Million | +46.26% |
| Other Changes | €2.42 Million | +4.73% |
| Total Change | €- | -33.41% |
Book Value vs Market Value Analysis
This analysis compares Osmotica Pharmaceuticals plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €7.35 | €0.00 | x |
| 2019-12-31 | €2.21 | €0.00 | x |
| 2020-12-31 | €1.50 | €0.00 | x |
| 2021-12-31 | €0.92 | €0.00 | x |
| 2022-12-31 | €0.52 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Osmotica Pharmaceuticals plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -101.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -103.96%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.52x
- Recent ROE (-101.17%) is above the historical average (-107.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -28.32% | -41.48% | 0.33x | 2.06x | €-148.02 Million |
| 2019 | -236.17% | -112.86% | 0.52x | 4.04x | €-282.37 Million |
| 2020 | -84.80% | -286.68% | 0.07x | 3.95x | €-88.97 Million |
| 2021 | -84.61% | -370.95% | 0.12x | 1.89x | €-72.59 Million |
| 2022 | -101.17% | -103.96% | 0.39x | 2.52x | €-56.80 Million |
Industry Comparison
This section compares Osmotica Pharmaceuticals plc's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.